NAD+ IV infusions vs supplements: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtag context, this creator is almost certainly arguing that NAD+ delivered intravenously or via injection is categorically superior to oral supplementation, and that pills produce "poor absorption" and "minimal results." The framing is aggressive: IV wins "every time," pills are a waste. The mention of "instant impact" and "100% bioavailability" suggests specific mechanistic claims are being made. The hashtag methyleneblue is also notable here, a compound with a very different pharmacological profile that has no obvious connection to NAD+ therapy, suggesting this account may be bundling multiple compounds under a general "biohacking" umbrella without clear clinical distinction. This is worth flagging before any transcript-level review.

What does the science actually show?

The bioavailability argument for IV NAD+ is technically sound but clinically overblown. Oral NAD+ precursors, specifically nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), do convert to NAD+ in peripheral tissue. Conze et al. (2019, Scientific Reports) showed that 1,000 mg/day of NR increased whole blood NAD+ by roughly 2.7-fold over eight weeks. Yoshino et al. (2021, Science) found NMN improved muscle insulin sensitivity in postmenopausal women, though the effect was modest. IV NAD+ does raise plasma NAD+ faster, but plasma NAD+ is not the same as intracellular NAD+ in target tissues, which is what actually matters metabolically. There is no published RCT demonstrating that IV NAD+ produces superior clinical outcomes to oral NR or NMN in healthy adults. The "100% bioavailability" claim is technically accurate for IV delivery but misleadingly implies superior efficacy, which has not been demonstrated.

Where does the social media noise diverge from clinical reality?

The gap between IV infusion marketing and actual clinical data is significant. Most NAD+ human trials use oral NR or NMN, not IV infusions, because that is the form studied. The few IV NAD+ studies that exist are small, often uncontrolled, and focused on addiction medicine contexts, not healthy aging or cognitive performance. Lautrup et al. (2019, Cell Metabolism) reviewed the NAD+ aging field extensively and noted that while NAD+ depletion is real with aging, the optimal delivery route for supplementation in humans remains unresolved. The "anti-aging" framing in this video is a significant leap. No human trial has demonstrated IV NAD+ reverses biological aging markers in healthy adults. The "cellular and brain support" claims are based on animal data and extrapolation, not human clinical endpoints. Regulatory agencies have not approved NAD+ infusion for any indication.

What should you actually know?

NAD+ precursor supplementation is a legitimate area of research, but IV infusion clinics are selling a premium delivery method that lacks comparative efficacy data over oral options. If you are considering NAD+ therapy for energy, cognition, or longevity, the oral evidence base is actually stronger than the IV evidence base simply because more studies exist using those forms. IV infusions carry real risks that oral supplements do not, including infection, phlebitis, and adverse reactions during infusion, which some clinics understate. The methyleneblue hashtag in this video is a separate concern: methylene blue has its own pharmacology and risks, particularly serotonin syndrome potential when combined with serotonergic agents. Bundling compounds without clinical context is exactly where telehealth consumers should slow down and ask direct questions of a licensed provider before committing to any protocol.